Neuroleptics are frequently used to treat behavioral problems inpatients with dementia. Yet, the elderly are particularly prone to neuroleptic side effects and adverse drug reactions. This paper examines the relationship between variable neuroleptic drug metabolism by cytochrome P450 2d6 and acute side effects in older patients. A noninvasive test of cytochrome P450 2d6 function was prospectively given to patients treated with fixed doses of perphenazine. This approach may help to reduce adverse drug reactions which increase exponentially with age.
TeriLRabinsPWhitehousePBergLReisbergBSunderlandTEichelmanBPhelpsC. Management of behavior disturbance in Alzheimer's Disease: Current knowledge and future directions. Alzheimer Dis Assoc Disordr.1992;6: 77–88.
4.
WildKVKayeJAOkenBS. Early noncognitive change in Alzheimer's disease and healthy aging. J Geriatr Psychiatry Neurol.1994;7:199–205.
5.
SteeleCRovnerBChaseGAFolsteinM. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry.1990;147:1049–1051.
6.
RubinBSDubeAHMitchellEK. Asphyxiai deaths due to physical restraint. Arch Fam Med.1993;2:405–408.
7.
MulsantBMGershonS. Neuroleptics in the treatment of psychosis in late life. A rational approach. Int J Geriatr Psychiatry.1993;8:979–992.
8.
SalzmanC. Treatment of agitation in the elderly. In: MeltzerHY, ed. Psychopharmacology: The third generation of progress.New York: Raven Press; 1987:1167–1176.
9.
PollockBGMulsantBH. Antipsychotics in older patients: A safety perspective. Drugs & Aging.1995;6:312–323.
10.
SaltzBLWoernerMGKaneJMLiebermanJAAlvirJBergmannKJBlankKKoblenzerJKahanerK. Prospective study of tardive dyskinesia incidence in the elderly. JAMA.1991;266: 2402–2406.
11.
JesteDVLacroJPGilbertPLKlineJKlineN. Treatment of late-life schizophrenia with neuroleptics. Schizophrenia Bull.1993;19:817–830.
Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services.Guideline for the study of drugs likely to be used in the elderly.1989.
14.
DawlingSCromeP. Clinical pharmacokinetic considerations in the elderly. Clin Pharmacokinet.1989;17:236–263.
15.
GershonSFerrisSKennedyJKurtzNOverallJPollockBGReisbergBWhitehouseP. Methods for the evaluation of pharmacologic agents in the treatment of cognitive and other deficits in dementia. In: Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines.PrienRFRobinsonDS, Eds. New York: Raven Press; 1994:467–499.
16.
ZimmerAWCalkinsEHadleyEOstfeldAMKayeJMKayeD. Conducting clinical research in geriatric populations. Ann Int Med.1985;103: 276–283.
17.
SchmuckerDLWoodhouseKWWangRKWynneHJamesOFMcManusMKremersP. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther.1990;48:365–374.
18.
AxelssonRMartenssonE. Serum concentration and elimination from serum of thioridazine in psychiatric patients. Curr Ther Res.1976; 19: 242–265.
19.
HansenLBLarsenN-E. Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology.1985;87:16–19.
20.
YesavageJAHolmanCACohnR. Correlation of thiothixene serum levels and age. Psychopharmacology.1981;74:170–172.
21.
PollockBG. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry.1994;2:204–213.
22.
TyndaleRKalowWInabaT. Oxidation of reduced haloperidol to haloperidol: Involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol.1991;31: 655–660.
23.
LlerenaAAlmCDahlM-LEkqvistBBertilssonL. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype. Ther Drug Monit.1992;14:92–97.
24.
PollockBGPerelJMAltieriLKirshnerMYeagerAHouckPReynoldsCF. Debrisoquine hydroxylation phenotyping in geriatric psycho-pharmacology. Psychopharmacol Bull.1992;28: 163–168.
25.
EvansDAPMaghoubASloanTPIdleJRSmithRL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a British population. J Med Genet.1980; 17: 102–105.
26.
PollockBGMulsantBHSweetRARosenJAltieriLP. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull.1995;31:327–331.
27.
RosenJMulsantBWrightB. Agitation in severely demented patients. Ann Clin Psychiatry.1992;4:207–215.
28.
Dahl-PuustinenM-LLidenAAlmCNordinCBertilssonL. Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther.1989;46:78–81.
29.
LingjaerdeOAhlforsUGBechPDenckerSJEigenK. The UKU side effect rating scale. Acta Psychiatr Scan.1987;334(Suppl):1–100.
30.
SimpsonGMAngusJWS. A rating scale for extrapyramidal side effects. Acata Psychiatr Scand. [Suppl]1970;212:11–19.
31.
LlerenaAHerraizAGCobaledaJJohanssonIDahlM-L. Debrisoquine and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther.1993;54: 606–611.
32.
AbernethyDRGreenblattDJShaderRI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther.1985;232: 183–188.
33.
PeckCCTempleRCollinsJM. Understanding consequences of concurrent therapies. JAMA.1993;269:1550–1552.
34.
GhoseK. The need for a review journal of drug use and the elderly. Drugs & Aging.1991;1:2–5.
